Skip to content

A comparative study on the safety and efficacy of CT-guided and 3D-printed template-assisted CT-guided radioactive iodine-125 seed implantation as a salvage treatment for recurrent head and neck cancer after radiotherapy

A comparative study on the safety and efficacy of CT-guided and 3D-printed template-assisted CT-guided radioactive iodine-125 seed implantation as a salvage treatment for recurrent head and neck cancer after radiotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300073810
Enrollment
Unknown
Registered
2023-07-21
Start date
2023-07-23
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

head and neck cancer

Interventions

CT-guided radioactive iodine-125 seed implantation:None
3D-printed template-assisted CT-guided radioactive iodine-125 seed implantation:None

Sponsors

Peking University Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2. The head and neck cancer have received external beam radiation therapy in the past; 3. Pathologically diagnosed with recurrent head and neck cancer; 4. Suitable for radioactive seed implantation needs; 5. No bleeding tendency, no serious or uncontrolled underlying diseases; 6. There are suitable puncture routes, and the expected therapeutic dose can be reached after implantation of radioactive seeds; 7. KPS >= 60, expected to be able to tolerate puncture/radioactive iodine-125 seed implantation, and the expected survival time greater than 3 months.

Exclusion criteria

Exclusion criteria: 1. Subjects with skin infection at the puncture site; 2. The lesion is close to the important organs or has a large range of liquefactive necrosis and the seed distribution is expected poor; 3. Subjects who are pregnant, lactating or mentally ill; 4. Poor compliance, unable to complete the treatment; 5. The researcher considers not suitable for participating in this clinical trial.

Design outcomes

Primary

MeasureTime frame
Safety;

Secondary

MeasureTime frame
Objective response rate;Local control;Progress free survival;Overall survival;Dosimetric parameters;

Countries

China

Contacts

Public ContactJunjie Wang

Peking University Third Hospital

junjiewang@pku.edu.cn+86 137 0107 6310

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026